F Opdam
Antoni van Leeuwenhoek/The Netherland Cancer Institute · The Netherlands Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name F Opdam as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:20 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05518799 · CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid TumoursThe Netherlands Cancer Institute · completed · Prostate Cancer, Solid Tumor, Adult · principal investigator
- Ph1/Ph2NCT02450656 · Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerThe Netherlands Cancer Institute · unknown · Colorectal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms · principal investigator
- Ph1/Ph2NCT02230553 · Lapatinib Plus Trametinib in KRAS Mutant NSCLCThe Netherlands Cancer Institute · completed · Colorectal Cancer · study director
- Ph1/Ph2NCT02039336 · Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCThe Netherlands Cancer Institute · completed · Colorectal Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:20 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.N Engl J Med · 2025122 citationsRCR 24.2
- First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).J Immunother Cancer · 202368 citationsRCR 4.9
- WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.Gynecol Oncol · 202345 citationsRCR 3.7
- 45 citationsRCR 8.1
- 41 citationsRCR 1.2
- Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.Cancer Chemother Pharmacol · 202034 citationsRCR 1.1
- Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.Oncologist · 202132 citationsRCR 1.4
- 15 citationsRCR 3.2
- Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).Eur J Cancer · 202312 citationsRCR 1.0
- The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients.Eur J Intern Med · 20109 citationsRCR 0.3